Your Centre for New Zealand News

Join the Newsletter

Study shows Pfizer COVID vaccine’s temporary protection and challenges with variants

Summarised by Centrist 

A recent study by Louisiana State University, published in the Vaccine journal, reveals that Pfizer’s COVID vaccines and boosters offer only temporary protection against the virus. The research, titled “Dynamics of Serum-Neutralizing Antibody Responses in Vaccinees through Multiple Doses of the BNT162b2 Vaccine,” involved 16 participants who received two primary doses and a booster of the Pfizer vaccine. 

The study found that while initial antibody responses were strong, they quickly diminished, returning to pre-vaccination levels within four to six months. Moreover, the vaccines showed decreased effectiveness against newer COVID variants, particularly Omicron, even when antibody levels were at their peak. The study also noted significant increases in two different  antibodies, suggesting potential immune tolerance, which means the immune system becomes less reactive to the vaccine’s spike protein, helping to prevent overreaction or adverse effects. The spike protein is a part of the virus that the body produces in response to mRNA vaccines, and it plays a role in how the virus enters cells.

Read more over at Western Standard

Enjoyed this story? Share it around.​

Subscribe
Notify of
guest
5 Comments
Most Voted
Newest Oldest
Inline Feedbacks
View all comments

Read More

NEWS STORIES

Sign up for our free newsletter

Receive curated lists of news links and easy-to-digest summaries from independent, alternative and mainstream media about issues affect New Zealanders.

Sign up for our free newsletter

Receive curated lists of news summaries from independent, alternative and mainstream media about issues affecting New Zealanders.

You’ll also receive our NZ News Essentials newsletter. You can unsubscribe from either at any time.